Research programme: ubiquitin specific protease inhibitors - HybrigenicsAlternative Names: HBX 19,818; HBX 41,108; USP inhibitors - Hybrigenics
Latest Information Update: 28 Apr 2012
At a glance
- Originator Hybrigenics
- Class Small molecules
- Mechanism of Action Ubiquitin-protein ligase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cancer